Categories Earnings, Health Care

Catalyst Pharmaceutical (CPRX): Q4 2019 Earnings Snapshot

— Catalyst Pharmaceutical (NASDAQ: CPRX) reported its fourth-quarter 2019 earnings of $0.07 per share versus $0.10 per share expected.

Earnings Update by AlphaStreet

— Total revenue soared to $30.12 million from $500 thousand a year ago. The analysts estimated revenue of $29.4 million for the fourth quarter.

— Selling, general and administrative expenses jumped by 65% year-over-year while research and development expenses fell by 25%.

— Looking ahead into fiscal 2020, the company still expects Firdapse net revenues to be in the range of $135-155 million.

— The company expects to report top-line results from the phase 3 trial for myasthenia gravis (MG) patients with autoantibodies to muscle-specific tyrosine kinase (MuSK) in the second quarter of 2020.

— Catalyst expects to report top-line results from the SMA Type 3 proof of concept trial in the second quarter of 2020. It predicts potential approval of New Drug Submission (NDS) for Firdapse to treat LEMS in Canada in the second half of 2020.

— Assuming the MuSK-MG trial is successful, the company hopes to submit a supplemental NDA for Firdapse for MuSK-MG around the end of 2020.

— In the face of the coronavirus Covid-19 outbreak, the company has been asked to provide a continuous uninterrupted supply of Firdapse. As of today, Catalyst has more than an adequate supply of Firdapse ready for shipment in the warehouse to meet patients’ needs through the end of this year.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Macy’s (M), Target (TGT), Dollar Tree (DLTR): Major retailers and a costly holiday season

The holiday season has started and it is the time for cheer but this year inflation is proving to be a major spoilsport for the festivities. As customers struggle to

Here’s a look at Dollar Tree’s (DLTR) expectations for the remainder of the year

Shares of Dollar Tree Inc. (NASDAQ: DLTR) were down over 1% on Wednesday, a day after the company reported earnings results for the third quarter of 2022. Revenue and earnings

Target Corporation (TGT): A look at how the retail giant is shaping up against an inflationary backdrop

Shares of Target Corporation (NYSE: TGT) were up over 1% on Wednesday. The stock has dropped 30% year-to-date and 35% over the past 12 months. Last week the company reported

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top